Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Daniel O'Day
Biotech
After 3 acquisitions, Gilead shifts focus to expanded pipeline
After entering 2026 hungry for deals, Gilead Sciences has wasted no time eating its fill.
Darren Incorvaia
Apr 8, 2026 4:00am
JPM26: Gilead eyes new deals from a 'position of strength'
Jan 14, 2026 3:30am
Gilead's O'Day relishes reunion as Berger agrees to leave Sanofi
Dec 13, 2024 5:20am
CymaBay board pushed for 50 cent top up to Gilead's $32.50 offer
Feb 26, 2024 10:49am
Gilead hits go on a host of Arcus cancer programs
Nov 18, 2021 8:00am
Gilead poaches Amgen exec Flavius Martin to run its R&D
Mar 26, 2021 9:40am
